The difference in clinic-pathological features between signet ring cell carcinoma and gastric mucinous adenocarcinoma

Tumor Biology ◽  
2013 ◽  
Vol 34 (5) ◽  
pp. 2625-2631 ◽  
Author(s):  
Hao Jiang ◽  
Hongfeng Zhang ◽  
Lantian Tian ◽  
Xi Zhang ◽  
Yingwei Xue
Keyword(s):  
Cell Carcinoma ◽  
Mucinous Adenocarcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Pathological Features ◽  
Signet Ring ◽  
Ring Cell ◽  
The Difference

Primary signet ring cell carcinoma of colon: Retrospective analysis of VACCR database.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 58-58 ◽  
Author(s):  
R. Thota ◽  
T. Tashi ◽  
W. Gonsalves ◽  
V. Murukesan ◽  
P. Townley ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cell Carcinoma ◽  
Mucinous Adenocarcinoma ◽  
Cell Cancer ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Lymph Node Status ◽  
Signet Ring ◽  
Ring Cell ◽  
Carcinoma Of Colon

58 Background: Signet ring cell carcinoma accounts for less than 1% of all colon cancers. We examined the clinical pathological features and prognosis of signet ring cell carcinoma of colon and compare it with mucinous and non-mucinous adenocarcinoma of colon. Methods: A total of 206 patients diagnosed with signet ring cell carcinoma from 1995 to 2009 were identified from the VA Central Cancer Registry (VACCR) database. Age, race, histology, grade, lymph node status, stage and type of treatment received data were collected. Results: Out of 206 patients, 173 (83.9%) were white, 31 (15%) were black, and 2 patients were listed as unknown. Median age of diagnosis was 67 years as compared to 70 years for both mucinous and non-mucinous adenocarcinoma of colon. Pathological T-stages were as follows: T1 = 2.9%, T2=5.3%, T3=33.9%, T4= 25.7%, and unknown 32%. Of the total, 22.3% were located in caecum, 21.8% in ascending colon, 15.5% in sigmoid colon, 7.7% in appendix and hepatic flexure of colon, 11.1% in transverse colon, 2.9% in splenic flexure and 4.4% in descending colon. 33.5% were lymph node positive, 34.6% were lymph node negative, and 31.8% were unknown. Histologically grade 3 (55.4%) was most commonly reported followed by grade 2 (7.3%), grade 1 (2.5%), grade 4 (1.9%)and in 33% grade was unknown. 41.3% patients received only surgery while 34% received surgery with adjuvant chemotherapy, 7.3% received chemotherapy alone and 7.8% patients received either chemotherapy, radiation or hormonal therapy alone, 9% did not receive any therapy. 1 year, 3 year and 5 year survivals for signet ring cell cancer compared to adeno carcinoma was 60% vs 80%, 33% vs 60%, and 24% vs 47% respectively. Median survival of signet ring cell carcinoma compared to mucinous and non mucinous adenocarcinoma was 19 months, 48 months and 62 months respectively. Conclusions: Signet ring cell carcinoma of colon has poor survival rates than the other histological subtypes. Signet ring cell carcinoma presents at an earlier age, higher tumor grade and advanced stage at diagnosis when compared to mucinous and non-mucinous adenocarcinoma of colon. Due to rarity of this disease further multi-institute studies are required for in-depth understanding and analysis of this disease. No significant financial relationships to disclose.

scholarly journals Gastric Signet Ring Cell Carcinoma: A Comparative Analysis of Clinicopathologic Features

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482097659
Author(s):  
Boubacar Efared ◽  
Mohamed Kadi ◽  
Laila Tahiri ◽  
Nada Lahmidani ◽  
Karim Ibn Majdoub Hassani ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Clinicopathologic Features ◽  
Histological Subtype ◽  
Macroscopic Appearance ◽  
Signet Ring ◽  
Ring Cell ◽  
The Difference

Signet ring cell carcinoma (SRC) is a distinct histological subtype of gastric carcinoma. Our aim is to investigate differential characteristics between gastric SRC and other non SRC carcinomas (nSRC). It was a retrospective study including 183 patients diagnosed with gastric carcinoma over a period of 5 years at our pathology department. We performed statistical comparison of clinicopathological features between patients with SRC and those with nSRC. 127 patients (69.4%) had nSRC, 56 had SRC (30.6%), the mean age was 56.67 ± 14.03 years. Patients with SRC were younger than those with nSRC (mean age of 49.66 versus 59.76, P = 0.030). Patients with SRC tend to have more diffuse tumors in the stomach ( P = 0.005), with flat macroscopic appearance ( P = 0.001). Patients with SRC present more often with pT3 tumors ( P < 0.001), lymph node metastasis ( P = 0.024) and perineural invasion ( P = 0.003). There were no significant differences between SRC and nSRC in gender, vascular invasion or distant metastasis ( P > 0.05). The median survival time was 42.82 ± 1.70 months. Patients with nSRC live longer than those with SRC, but the difference was not significant ( P = 0.28). SRC is a histological subtype of gastric carcinoma with distinctive clinicopathologic features. The clinical management of patients should take into account these particular features.

Effect of neoadjuvant treatment on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma: A post-hoc analysis from 3 prospective studies.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3608-3608
Author(s):  
Jianwei Zhang ◽  
Yanhong Deng ◽  
Yue Cai ◽  
Huabin Hu ◽  
Zehua Wu ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Mucinous Adenocarcinoma ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Signet Ring ◽  
Tumor Downstaging ◽  
Ring Cell

3608 Background: Mucinous adenocarcinoma and signet-ring cell carcinoma were uncommon in locally advanced rectal cancer. And it has been reported that both mucinous adenocarcinoma and signet-ring cell carcinoma showed poor response to standard neoadjuvant chemoradiotherapy. Here, we tried to compare the efficacy of different neoadjuvant treatment regimen on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma (M/S). Methods: We enrolled patients with locally advanced rectal cancer from 3 prospective clinical trials (NCT01211210, NCT02217020 and NCT02887313), including FOWARC study (N = 309), mFOLFOXIRI neoadjuvant chemotherapy trial (N = 103) and the total neoadjuvant treatment with FOLFOX and radiotherapy (N = 129). Among the 541 patients, 41 (7.6%) patients were M/S and 500 were non-M/S. Totally, 7 M/S patients and 84 non-M/S patients received 5FU concurrent with radiotherapy (Group A), 20 M/S patients and 208 non-M/S underwent FOLFOX concurrent with radiation or total neoadjuvant treatment (Group B), 11 M/S patients and 92 non-M/S patients underwent mFOLFOXIRI neoadjuvant chemotherapy alone (Group C). Other 3 M/S patients and 116 non-M/S patients received FOLFOX neoadjuvant chemotherapy alone (Group D). Results: Among M/S patients, only 4 (9.7%) achieved pathologic complete response (pCR), and 6 (14.6%) patients had tumor downstaging to ypstage 0-I. In group A, the pCR rate was 14.3% and 11.9% (p = 0.85), and the tumor downstaging rate was 14.3% and 36.9% (p = 0.22) in M/S and non-M/S patients, respectively. In group B, the pCR rate was 15.0% and 34.6% (p = 0.07), and the tumor downstaging rate was 25.0% and 60.1% (p = 0.002) in M/S and non-M/S patients, respectively. However, in group C and group D with chemotherapy alone as neoadjuvant treatment, no M/S patients showed pCR or tumor downstaging; while in non-M/S patients higher tumor downstaging rate was observed. Conclusions: M/S showed resistance to neoadjuvant chemotherapy along regimens. Even with chemoradiotherapy, M/S patients showed poorer response than that of non/M/S patients. Further study was warranted to explore the new regimen for M/S patients. [Table: see text]

scholarly journals Adverse Histological Features Alone Was Not Sufficient for Decision of Adjuvant Chemotherapy in T3N0M0 colonic cancer: A Propensity Score Matching Study Based on Population Analysis

2021 ◽  
Author(s):  
Qinghua Wang ◽  
Hongjuan Zheng ◽  
Xiaoxiao Chen ◽  
Xia Zhang ◽  
Xiayun Jin ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
Cell Carcinoma ◽  
Mucinous Adenocarcinoma ◽  
Survival Benefit ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Histological Features ◽  
Signet Ring ◽  
Ring Cell

Abstract Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Approximately 25% of patients with AJCC stage II suffered recurrence after radical surgery, but the role of adjuvant chemotherapy in Stage II CRC is controversial. We aimed to evaluate the benefit from chemotherapy for T3N0M0 patients with adverse histological features. Methods: An analysis of the Surveillance, Epidemiology, and End Results (SEER) 18 databases was performed to identify patients underwent radical resection 20-80 years old with colonic carcinoma diagnosed during year 2004 to 2012. Poorly differentiated, undifferentiated, mucinous adenocarcinoma and signet ring cell carcinoma (SRCC) were defined as adverse histological features, and well or moderately differentiated adenocarcinoma as good histological features. Multivariate analyses were used to adjust the effects of other covariates. The survival benefit of adjuvant chemotherapy was demonstrated in the propensity score matching cohort. Results: The adjuvant chemotherapy brought no survival benefit (good histological features HR, 1.076; 95% CI, 0.957-1.211; P=0.220; adverse histological features HR, 0.995; 95% CI, 0.777-1.274; P=0.967); Neither mucinous adenocarcinoma nor signet ring cell carcinoma brought a significance on survival (mucinous adenocarcinoma HR, 0.699; 95% CI, 0.488-1.002; P=0.051; signet ring cell carcinoma HR, 0.750; 95% CI, 0.386-1.459; P=0.397) compared to adenocarcinoma. Left-side colon was associated with a poorer survival in good histological features group (HR, 1.136; 95% CI, 1.034-1.248; P=0.008). Conclusions: The adverse histological features don’t influence on survival for patients with T3N0M0 staging, and adjuvant chemotherapy is invalid to improve the survival for these patients, indicating adverse histological features alone was not sufficient for decision of adjuvant chemotherapy in this situation rather than the recommendation of the guidelines.

Sign in / Sign up

Export Citation Format

Share Document